Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : Biocon Biologics
Deal Size : $150.0 million
Deal Type : Collaboration
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln
Details : The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.
Brand Name : ACTIBLOK IPR 25
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 13, 2024
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : Biocon Biologics
Deal Size : $150.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
